# Cipherome

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cipherome

- Industry: Biotechnology
- Headquarters: San Jose, US
- Website: www.cipherome.com
- Total disclosed funding: $16M
- Latest round: Series B (Feb 14, 2022)
- Investors on record: 4

## About

Based in California, US, and founded in 2015, Cipherome, Inc. operates as an Artificial Intelligence (AI) and bioinformatics company, focused on the development of a technology platform, intended to predict ADRs (Adverse Drug Reactions) related to various medications, thereby allowing patients to receive quality and safe treatment and care. In February 2022, the company raised KRW 19.5 billion in series B funding from new investors InterVest, Medivate Partners, Nautilus Venture Partners, and signite partners. As of 2022, the firm is being led by its CEO, Ilsong Lee.

Cipherome, Inc. develops and offers a patented technology platform called Xentinel®, that uses artificial intelligence (AI) to analyze an individual's genetic variants or genomics, as well as clinical factors like weight, patient age, chronic diseases, medications, and so on, to predict the risk for adverse drug reactions (ADRs) in patients who consumes a specific drug. The company's technology enables healthcare professionals to personalize medication to a specific patient, thereby reducing the effects of ADRs, while ensuring quality patient care.

## Funding rounds

- Series B, Feb 14, 2022, $16M — InterVest, Nautilus Venture Partners, LINEA Investment, Signite

## Investors

- InterVest (https://capitalatlas.ai/funds/intervest) — Series B
- Nautilus Venture Partners (https://capitalatlas.ai/funds/nautilus-venture-partners) — Series B
- LINEA Investment (https://capitalatlas.ai/funds/linea-investment) — Series B
- Signite (https://capitalatlas.ai/funds/signite) — Series B